Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab in IV Steroid-Refractory Ulcerative Colitis
NCT00502294Phase 3Withdrawn
- Sponsor
- Facet Biotech Corporation
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of visilizumab in ulcerative colitis (UC), sponsored by Facet Biotech Corporation. Status: withdrawn.
02
Drugs
visilizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00502294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502294.